Clinical Trial Update: Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 study examining the combination of sorafenib and temsirolimus in patients with metastatic, recurrent, or unresectable melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Nexavar (Sorafenib)
• Torisel (Temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Recurrent Melanoma | Phase 1 | Status: COMPLETED